

ABSTRACT

A method for consistently producing a pure population of activated, polyclonal, Th1 memory cells for use in adoptive immunotherapy without

- 5 the use of any exogenous cytokines and without significant subject-to-subject variation is provided. These cells obtain a surface phenotype that enables their trafficking to tumors and other sites of inflammation upon infusion and can be reinfused into the a subject to enhance the cellular immune response and/or switch the predominant immune response from
- 10 Th2-dominated to a Th1-dominated immune response.